6 results about "Alanine transaminase" patented technology

The present invention relates to binding proteins which bind alanine aminotransferase (ALT). The present invention also relates to bivalent, trivalent, quadrivalent or multivalent binding proteins that bind ALT. The present invention also relates to nucleic acids, vectors and host cells for producing such binding proteins, methods for producing such binding proteins, kits comprising such binding proteins and methods and uses of such binding proteins.

The invention discloses an engineering strain for producing glycine. The engineering strain is obtained by modifying the following steps: (i) respectively introducing an exogenous acetyl coenzyme A synthetase gene acs, an isocitrate lyase gene aceA and an isocitrate dehydrogenase kinase gene aceK; (ii) introducing a glutamic acid glyoxylate transaminase gene cgaT from quinoa; and (iii) respectively knocking out a DNA (Deoxyribose Nucleic Acid) binding transcription inhibition factor gene iclR, a glycine dehydrogenase gene gcvP, an alanine transaminase gene alaA, a malate dehydrogenase gene maeA and a malate synthetase G gene glcB. According to the invention, an engineering strain capable of efficiently synthesizing glycine is constructed by transforming a glycine biosynthesis metabolic pathway, and the strain can produce glycine by fermentation with glucose as a carbon source and has a relatively high conversion rate.

The invention relates to an alanine transaminase (ALT) detection reagent and a preparation method thereof, and belongs to the field of medical detection. The glutamic-pyruvic transaminase detection reagent is a nano antibody AC1 and AT1 which are combined with different binding sites of ALT, the nano antibody AC1 is immobilized on an avidin ELISA plate through biotinylation to serve as a capture antibody, and the nano antibody AT1 serves as a detection antibody. The glutamic-pyruvic transaminase detection reagent prepared based on the nano antibody and the detection method can meet the rapid and accurate glutamic-pyruvic transaminase detection requirements.

The main purpose of the present invention is to provide monascus and a composition for preventing or treating non-alcoholic fatty liver disease, the composition comprising the monascus and / or a monascus fermentation product thereof, or a functional component comprising the monascus fermentation product. The invention also aims to provide application of the monascus in preparation of the composition for preventing or treating the non-alcoholic fatty liver disease. The composition not only has the efficacy of reducing accumulation of total cholesterol (TC) and triglyceride (TG) in the non-alcoholic fatty liver disease caused by obesity, but also has the efficacy of reducing serum liver function indexes of asparaginic acid transaminase (AST) and alanine transaminase (ALT), so that the composition has the efficacy of preventing or treating the non-alcoholic fatty liver disease and related metabolic diseases thereof. , for example hyperlipidemia.

The application belongs to the technical field of biomedical detection and electrochemical sensor, and relates to a preparation method and application of a glutamate-pyruvate transaminase biosensor. A soluble metal salt containing cobalt cyanide ions is added into deionized water; copper salt and a complexing agent are uniformly dispersed with deionized water, and after mixing, a complexing reaction is carried out, and then filtration is carried out; the obtained solid is washed and dried, and then is uniformly mixed with polyvinylpyrrolidone, centrifuged, calcined, and CuCo / C nanoparticles are obtained, which are fixed on a gold electrode to obtain a working electrode. Glutamate oxidase, L-alanine and alpha-ketoglutaric acid are uniformly mixed with chitosan to obtain an enzyme solution, and a glutamate-pyruvate transaminase sensor is obtained by dropwise addition. The glutamate-pyruvate transaminase biosensor prepared by the application has a wide linear range and good sensitivity.

The invention discloses a traditional Chinese medicine composition for improving drug-induced liver injury, and belongs to the technical field of biological medicines. The traditional Chinese medicine composition is prepared from, by weight, 5-15 parts of radix bupleuri, 5-15 parts of rhizoma atractylodis macrocephalae, 5-15 parts of radix paeoniae alba, 5-15 parts of radix angelicae sinensis, 1-9 parts of honey-fried licorice roots, 5-15 parts of poria cocos, 2-11 parts of mint and 2-11 parts of fresh ginger. The composition provided by the invention can reduce the activity of alanine transaminase and glutamic oxalacetic transaminase in serum, improve drug-induced liver injury and improve the abundance of intestinal total bacteria. And the abundance of the lactobacillus acidophilus in the intestinal tract is improved by more than 7 times by a model group. The composition can reduce infiltration of intestinal inflammatory cells, increase the number of goblet cells and expression of intestinal tight junction protein ZO-1, and improve related symptoms caused by decrease of the intestinal barrier function.